Post : Junior Research Fellow/ Project Associate I
No. of Vacancy : One
Language : English, Kannada
Location : Bangalore, Karnataka
Experience :M.Sc. in Immunology with 1 year experience gained through a Masters Project
Application due date : 10th April, 2021
Salary : Rs. 31000+24% HRA as per DBT Sanction order
Junior Research Fellow (JRF)
Post Graduate Degree in Basic Science OR Graduate/Post Graduate Degree in Professional Course selected through a process described through any one of the following:
- Scholars who are selected through National Eligibility Tests-CSIR-UGC NET including lectureship (Assistant Professorship) and GATE
- The selection process through National level examinations conducted by Central Government Departments and their agencies and institutions such as DST, DBT, DAE, DOS, DRDO, MHRD, ICAR, ICMR, IIT, IISc, IISER etc.
Master’s Degree in Natural or Agricultural Sciences/ MVSc or Bachelor’s Degree in Engineering or Technology or Medicine from recognized University or equivalent.
Brief Description about the Project:
Despite the availability of flu vaccines for decades, influenza is still an important disease in both developing and developed countries with 500,000 casualties annually and many more people affected. From a global health perspective, the lack of effectivity, availability, affordability and accessibility of flu vaccines significantly limits our ability to respond to the seasonal flu every year and in the event of a pandemic. Currently, a low vaccine effectivity of 40% implies that 60% of vaccinated people are not sufficiently protected, with low confidence further contributing to limited uptake/immunization. In this project, public and private R&D organizations in India, EU and US collaborate on the development of two novel influenza vaccine concepts that meet the requirements of global vaccination, aiming to achieve <10>
The first approach combines a low dose of a commercial, inactivated, seasonal flu vaccine with a novel, potent adjuvant, and will deliver proof-of-concept in Phase I and IIa trials within 5 years.
The second approach builds on three innovations: 1) a novel recombinant HA with increased immunogenicity, 2) a potent adjuvant, and 3) an easy, needle-free delivery by intradermal patches. Contra-productive parts of HA will be removed to increase the immunogenicity of neutralizing epitopes. The adjuvant further stimulates protective immunity and immunological memory. The use of intradermal patches opens possibilities for self-administration, which will improve vaccine uptake in developing as well as developed countries. With proven nonclinical immunogenicity and safety, we will embark on clinical development of this concept after completion of the project. These plans differ in complexity and timelines but are realistic with chances to deliver next-generation flu vaccines for the globe.
To Apply : E-mail cover letter, CV, the names & contact details of Referees
To email@example.com cc firstname.lastname@example.org
For more information please visit our website www.sjri.res.in
Can Contact us on the following Numbers 080-49467010/49467011